Possibly. But only under medical supervision
Catch up on global daily news
Compelling long reads
Tune into captivating conversations
Watch engaging short films
Behind the scenes at The Economist
GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited…
A handpicked article read aloud from the latest issue of The Economist
The expiry of patents in China, India and elsewhere will boost uptake dramatically
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective and…
As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for both…
To recover its lead in obesity drugs, Novo Nordisk is transforming itself
